JOP20160150B1 - Substituted quinazoline compounds and methods of use thereof - Google Patents

Substituted quinazoline compounds and methods of use thereof

Info

Publication number
JOP20160150B1
JOP20160150B1 JOP/2016/0150A JOP20160150A JOP20160150B1 JO P20160150 B1 JOP20160150 B1 JO P20160150B1 JO P20160150 A JOP20160150 A JO P20160150A JO P20160150 B1 JOP20160150 B1 JO P20160150B1
Authority
JO
Jordan
Prior art keywords
methods
compounds
quinazoline compounds
substituted quinazoline
activity
Prior art date
Application number
JOP/2016/0150A
Other languages
Arabic (ar)
Inventor
Liansheng Li
Jun Feng
Yuan Liu
Tao Wu
Yi Liu
Yun Oliver Long
Pingda Ren
Original Assignee
Araxes Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araxes Pharma Llc filed Critical Araxes Pharma Llc
Priority to JP2018502355A priority Critical patent/JP6869947B2/en
Priority to MX2018000777A priority patent/MX2018000777A/en
Priority to CA2993013A priority patent/CA2993013A1/en
Priority to EP16747678.7A priority patent/EP3325447A1/en
Priority to TW105123325A priority patent/TW201713630A/en
Priority to CN201680053297.5A priority patent/CN108026046B/en
Priority to PCT/US2016/043568 priority patent/WO2017015562A1/en
Priority to HK18111923A priority patent/HK1252622A1/en
Application granted granted Critical
Publication of JOP20160150B1 publication Critical patent/JOP20160150B1/en

Links

Abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
JOP/2016/0150A 2015-07-22 2016-07-21 Substituted quinazoline compounds and methods of use thereof JOP20160150B1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2018502355A JP6869947B2 (en) 2015-07-22 2016-07-22 Use of substituted quinazoline compound and its G12C mutant KRAS, HRAS and / or NRAS protein as an inhibitor
MX2018000777A MX2018000777A (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins.
CA2993013A CA2993013A1 (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
EP16747678.7A EP3325447A1 (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
TW105123325A TW201713630A (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and methods of use thereof
CN201680053297.5A CN108026046B (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and their use as inhibitors of G12C mutant KRAS, HRAS and/or NRAS proteins
PCT/US2016/043568 WO2017015562A1 (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
HK18111923A HK1252622A1 (en) 2015-07-22 2018-09-17 Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195636P 2015-07-22 2015-07-22
US201662342078P 2016-05-26 2016-05-26

Publications (1)

Publication Number Publication Date
JOP20160150B1 true JOP20160150B1 (en) 2021-08-17

Family

ID=60244722

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0150A JOP20160150B1 (en) 2015-07-22 2016-07-21 Substituted quinazoline compounds and methods of use thereof

Country Status (2)

Country Link
AR (1) AR105458A1 (en)
JO (1) JOP20160150B1 (en)

Also Published As

Publication number Publication date
AR105458A1 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
MX2018000777A (en) Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins.
EA033689B9 (en) Inhibitors of kras g12c
PH12019550248A1 (en) Covalent inhibitors of kras
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
MX2021005924A (en) Compounds and methods of use thereof for treatment of cancer.
MX2021000887A (en) Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer.
MX2017013275A (en) Fused-tricyclic inhibitors of kras and methods of use thereof.
JO3805B1 (en) Inhibitors of kras g12c
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
PH12016501750A1 (en) Human plasma kallikrein inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2019009501A (en) Amino pyrimidine compounds useful as ssao inhibitors.
MX2021010297A (en) Human plasma kallikrein inhibitors.
MX2018011592A (en) Compound having mutant idh inhibitory activity, preparation method and use thereof.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2018007511A (en) Alkynyl dihydroquinoline sulfonamide compounds.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2017014301A (en) Compositions and methods for the treatment or prevention of pulmonary hypertension.
JOP20160150B1 (en) Substituted quinazoline compounds and methods of use thereof
WO2018067638A3 (en) High mobility group b1 protein inhibitors
MX2019014773A (en) Ccl2 inhibitors.
MY188058A (en) Inhibitors of kras g12c
EA202091668A3 (en) HUMAN PLASMA CALLICREIN INHIBITORS